Navigation Links
Spherix Shareholders Support Company's Focus on Naturlose, Biotechnology
Date:8/19/2007

Changes Approved for Board of Directors and Corporate Officers

BELTSVILLE, Md., Aug. 16 /PRNewswire-FirstCall/ -- Shareholders of Spherix Incorporated (Nasdaq: SPEX) voted to approve the sale of the Company's InfoSpherix subsidiary to The Active Network for $17 million in cash ($15 million at closing and $2 million following a 15-month escrow period). The vote was formally recorded at the Company's annual meeting at its headquarters in Beltsville, Maryland.

At the annual meeting, shareholders elected the following members to the Board of Directors:

-- Douglas T. Brown, Senior Vice President and Manager of the Corporate

Banking Government Contracting Group for PNC Bank

-- A. Paul Cox, Jr., Principal, Asset Protection Company

-- George C. Creel, former Executive VP and Chief Operating Officer,

Baltimore Gas and Electric Co.

-- Gilbert V. Levin, Ph.D., Spherix

-- M. Karen Levin, former VP for Spherix

-- Richard C. Levin, Spherix

-- Robert A. Lodder, Jr., Director of the Analytical Spectroscopy Research

Group of the Advanced Science and Technology Center at the University

of Kentucky

-- Robert J. Vander Zanden, Ph.D., former Vice President, R&D, Kraft Foods

International

In addition, Grant Thornton LLP was selected as the Company's independent accountants for the year 2007.

Richard Levin told shareholders that the phase 3 clinical trial for Naturlose as a diabetes treatment was going well and the entire study will now be conducted in the United States. The trial is scheduled to finish in early- to mid-2009, he said, noting, "Patient recruitment is going smoothly, patients have been on the drug for months now, and none have withdrawn. This is a very encouraging sign."

Levin said that the Company's primary goal is to interest a pharmaceutical partner in Naturlose. To that end he said, while the phase 3 trial is running, Spherix will put together a data package geared for the pharmaceutical industry. Levin said, "Perhaps most importantly, we will begin to develop the market. This includes educating potential users on the product and its benefits, and determining the best path to market."

Levin said that the Company is finalizing the protocol for a dose range study. An additional arm to the study will determine if Naturlose will work with one dose per day. Levin concluded his comments by saying, "I believe the biotech side of the company is positioned well for success. It will have a substantial cash reserve, an exciting product in a phase 3 clinical trial, and a solid leader in Dr. Claire Kruger. We could not have found a better person to lead us through this phase in the Company's history."

At a Board of Directors meeting later the same day, the Board elected Claire Kruger, Ph.D., as CEO of Spherix to replace Richard Levin, who will continue to manage InfoSpherix, becoming an employee of The Active Network. Dr. Kruger will also be responsible for building Spherix's new business line in health sciences consulting. Board member Robert Lodder, Ph.D., was elected President of Spherix.

In addition, the Board of Directors nominated Paul Cox as Chairman, and the following slate of Corporate Officers was elected:

-- Paul Cox, Chairman of the Board

-- Claire Kruger, CEO/COO

-- Robert Lodder, President

-- Katherine Brailer, Corporate Secretary and Director of Administrative

Services

-- Robert Clayton, Interim CFO and Treasurer

At this meeting, Gilbert Levin, Ph.D., was made Chairman Emeritus. In order to satisfy Sarbanes-Oxley regulations that the majority of the Board must be independent, Richard Levin and Karen Levin resigned from the Spherix Board of Directors, and Claire Kruger was elected as a Member.

Certain statements contained herein are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission, including the filing on Form 8-K made on March 3, 1999.

Under its motto, "A World of Solutions," Spherix's mission is to create value and increase shareholder wealth through innovations that benefit our clients and the human condition. Spherix offers innovations in information technology, knowledge management, and biotechnology.

Spherix's Internet address is http://www.spherix.com .


'/>"/>
SOURCE Spherix Incorporated

Copyright©2007 PR Newswire.

Related biology technology :

1. QIAGEN Instrument Service insist on the best in service and support
2. QIAGEN Instrument Service - insist on the best in service and support
3. Doyle urges Legislature to support biofuels program
4. CDW buyer supports Berbee growth plans
5. Doyle urges support of higher education spending
6. Doyle joins governors in support of stem cell bill
7. Wisconsin firms pledge to support healthcare IT standards
8. Rockwells $1M gift to UWM will support advanced automation research
9. MATC bio-diesel reactor to support training
10. Computer recycling: An environmental mandate the private sector can support
11. Net neutrality will be back, supporters vow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017  Aethlon Medical, Inc. (Nasdaq: ... authored by its Chairman and CEO, Jim Joyce ... Munich Security Conference last Saturday, Bill Gates ... kill more people than nuclear weapons. Mr. Gates expressed ... U.K. intelligence agencies, that scientific terrorists have access to ...
(Date:2/24/2017)... China Cord Blood Corporation (NYSE: CO ) ... blood collection, laboratory testing, hematopoietic stem cell processing and ... results for the third quarter and first nine months ... Third Quarter of Fiscal 2017 Highlights ... increased by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)...  VWR Corporation (NASDAQ: VWR), the leading global independent provider ... today reported its financial results for the fourth quarter and ... 4Q16 record quarterly net sales of $1.13 ... basis. 4Q16 EMEA-APAC segment net ... the Americas net sales increased 2.5%, or down 0.9% on ...
(Date:2/23/2017)... Feb. 23, 2017 ... except per share data, unaudited)Three Months Ended December 31,Twelve ... Revenue $       ... 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  756025%297303(2)%Vimizim ...
Breaking Biology Technology:
(Date:2/22/2017)... With the biometrics market to exceed ... technologies that innovative and agile startups must incorporate ... the changing competitive landscape: multifactor authentication (MFA), point-of-sale ... "Companies can no longer afford to cut ... Dimitrios Pavlakis , Industry Analyst at ABI Research. ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
Breaking Biology News(10 mins):